VetClick
Menu Menu
Login

VetClick

/ News
Saturday, 4th May 2024 | 4,385 veterinary jobs online | 122 people actively seeking work | 5,486 practices registered

Veterinary Industry News

Send us your news
Matthew James has received the BSAVA PetSavers Veterinary Achievement Award

Matthew James has received the BSAVA PetSavers Veterinary Achievement Award

CVS Neurologist Receives BSAVA PetSavers Veterinary Achievement Award

4 months ago
489 views

Posted
11th January, 2024 14h59

Author
CVS UK Ltd


CVS neurologist, Matthew James at Dovecote Veterinary Hospital [1] has received the BSAVA PetSavers Veterinary Achievement Award 2024 for research providing insights into the approach to initial management of epileptic dogs in first opinion practice.

The award is presented to the first named author of the most valuable peer-reviewed research paper published in the previous 12 months, following a BSAVA PetSavers grant. Matthew’s award is in recognition of his paper Approach to initial management of canine generalised epileptic seizures in primary-care veterinary practices in the United Kingdom [2], which was selected by the BSAVA Committee as being the most valuable of those assessed, with respect to veterinary practice.

James’ study explored data collected as part of the Small Animal Veterinary Surveillance Network (SAVSNET) at the University of Liverpool. In total, clinical records concerning 3,150,713 consultations (917,373 dogs) were collected and analysed from 224 UK veterinary practices. This included the management of canine generalised epileptic seizures in 517 dogs up to 6 years of age.

It concluded that the majority (98%) of dogs presenting for a single epileptic seizure were not started on long-term therapy; in accordance with the approach recommended by the International Veterinary Epilepsy Task Force (IVETF). However, most dogs presenting with multiple seizures within a 24-hour period (cluster seizures) were not started on long term anti-seizure drugs (ASDs), and for those that were the most frequently chosen ASD was imepitoin. Therefore, management of cluster seizures in primary care practice appears to be an area that could be improved.

Key findings from the study included:

The paper also reported on factors potentially associated with prescription of ASDs. It stated that dogs who presented for cluster seizures (more than one epileptic seizure in a 24-hour period) were more likely to be prescribed ASDs, or to be referred to a specialist, than dogs without cluster seizures. Dogs that were neutered or microchipped were more likely to be started on ASDs following the initial presentation, perhaps suggesting that owners who take part in regular preventative healthcare prior to the onset of their dog’s seizures could be more willing to start therapy in the earlier stages of the disease. In addition, more than half of dogs with cluster seizures were not prescribed any ASDs. Given that the presence of cluster seizures is typically considered an indication to start long-term therapy by the IVETF, this may be one aspect of seizure management that could be improved in primary care practice.

Regarding the choice of anti-seizure drugs (ASDs), imepitoin was more frequently prescribed than phenobarbital in response to cluster seizures. But unlike phenobarbital, the paper highlighted that the market authorisation for imepitoin does not include the treatment of cluster seizures. Therefore veterinarians should be aware that the use of imepitoin for cluster seizures should be considered as “off-licence” - and has additional implications for obtaining informed consent.

These findings may ultimately contribute to improved cohesion in the management of canine epileptic seizures between primary care and referral institutions.


Matthew James, said: “We believe this research contributes to an improved understanding of the current management strategies for canine epilepsy in general practice and how this compares to the current guidelines advised by the IVETF. Given the prevalence of epileptic seizures within the UK canine population, as well as the large proportion of dogs that will be managed entirely within general practice without referral to a neurologist, it is vital to ensure that the level of care being provided is optimal. We therefore hope that this research ultimately supports and guides general practitioners in their approach to canine epilepsy, thereby improving the quality of life of affected dogs and their owners.”

The peer-reviewed paper has been published in The Journal of Small Animal Practice[3]. The research was also undertaken by CVS neurologist Laurent Garosi.

Matthew James BVM BVS MRCVS graduated from the University of Nottingham in 2017 before working in a busy first-opinion practice in Wiltshire, during which time he developed a passion for neurology. He then joined Dovecote Veterinary Hospital in 2020 and completed his residency in neurology and neurosurgery in 2023.
 

[1]https://dovecoteveterinaryhospital.co.uk/ 

[2] Which received a PetSavers grant in 2019

[3] https://onlinelibrary.wiley.com/doi/epdf/10.1111/jsap.13543?saml_referrer


More from CVS UK Ltd


You might be interested in...